MarketCap
Facebook
X
Telegram
Spero Therapeutics ROE Ratio | SPRO
Annual ROE Ratio Spero Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14.52 | -148.66 | 21.34 | -61.13 | -101.66 | -59.29 | -81.7 | -36.07 | -45.79 | - | -5180.61 | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 21.34 | -5180.61 | -567.9 |
Quarterly ROE Ratio Spero Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -50.33 | -87.66 | -74.05 | -100.22 | -94.55 | -102.53 | -61.53 | -67.5 | -63.04 | -61.37 | -48.2 | -84.22 | -158.15 | -188.93 | -168.41 | -188.52 | -173.11 | -109.54 | -57.04 | -71.35 | -64.5 | -61.54 | -45.21 | -78.72 | -88.14 | -92.59 | -81.78 | -57.45 | -42.77 | -33.69 | -36.07 | -43.28 | -79.96 | -117.09 | -153.62 | -121.36 | -61.72 | -45.74 | 15.87 | 13.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 15.87 | -188.93 | -82.14 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ARCA biopharma
ABIO
|
-22.34 | - | 1052.0 % | $ 415 M |  USA |
 |
Acasti Pharma
ACST
|
-12.2 | - | 4.01 % | $ 150 M |  Canada |
 |
ADiTx Therapeutics
ADTX
|
-768.34 | - | - | $ 374 | USA |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
51843.24 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
-32.34 | - | 1.93 % | $ 17.4 M | USA |
 |
Aileron Therapeutics
ALRN
|
-294.78 | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
-55.11 | - | 4.14 % | $ 49.1 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
6.05 | - | - | $ 5.18 B | USA |
 |
Athira Pharma
ATHA
|
-380.03 | - | - | $ 269 M | USA |
 |
Avenue Therapeutics
ATXI
|
-158.79 | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
-29503.56 | - | 1083.1 % | $ 745 M | USA |
 |
AstraZeneca PLC
AZN
|
21.0 | - | - | $ 96.9 B |  Britain |
 |
Brainstorm Cell Therapeutics
BCLI
|
103.22 | - | -2.5 % | $ 5.88 M | USA |
 |
BeiGene, Ltd.
BGNE
|
6.58 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bio-Path Holdings
BPTH
|
-6424.68 | - | - | $ 100 K | USA |
 |
Cara Therapeutics
CARA
|
-86.94 | - | -3.03 % | $ 260 M | USA |
 |
ChromaDex Corporation
CDXC
|
22.71 | - | -0.88 % | $ 598 M | USA |
 |
Caladrius Biosciences
CLBS
|
-111.65 | - | -16.75 % | $ 25.8 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
43.82 | - | -5.98 % | $ 34.1 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
43.82 | - | -4.36 % | $ 27 M | USA |
 |
Diffusion Pharmaceuticals
DFFN
|
-148.0 | - | 11.68 % | $ 8.97 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
49.5 | - | -5.68 % | $ 8.28 M | USA |
 |
Enochian Biosciences
ENOB
|
833.76 | - | - | $ 40.5 M | USA |
 |
Esperion Therapeutics
ESPR
|
7.51 | - | - | $ 661 M | USA |
 |
Evofem Biosciences
EVFM
|
-0.53 | - | 7.55 % | $ 38.1 M | USA |
 |
Eyenovia
EYEN
|
-110.36 | - | 49.81 % | $ 13.2 M | USA |
 |
FibroGen
FGEN
|
-610.73 | - | - | $ 889 M | USA |
 |
Homology Medicines
FIXX
|
70.93 | - | 0.77 % | $ 53.4 M | USA |
 |
Amicus Therapeutics
FOLD
|
-9.89 | - | - | $ 4.47 B | USA |
 |
Frequency Therapeutics
FREQ
|
-227.96 | - | - | $ 528 M | USA |
|
Galecto
GLTO
|
-87.29 | - | - | $ 762 M |  Danmark |
 |
GlycoMimetics
GLYC
|
0.08 | - | 9357.83 % | $ 1.01 B | USA |
 |
Graybug Vision
GRAY
|
445.14 | - | -11.23 % | $ 9.65 M | USA |
|
Galera Therapeutics
GRTX
|
3750.6 | - | -32.59 % | $ 7.61 M | USA |
 |
Happiness Biotech Group Limited
HAPP
|
-40.75 | - | 1.35 % | $ 17.8 M |  China |
 |
Hepion Pharmaceuticals
HEPA
|
-310.32 | - | -18.79 % | $ 39.3 K | USA |
 |
Hoth Therapeutics
HOTH
|
-202.73 | - | - | $ 18.8 M | USA |
 |
IMARA
IMRA
|
-22.56 | - | 15.96 % | $ 663 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
4039.1 | - | - | $ 1.45 B | Britain |
 |
KemPharm
KMPH
|
53.82 | - | -0.34 % | $ 200 M | USA |
 |
Kezar Life Sciences
KZR
|
-79.96 | - | - | $ 53.3 M | USA |
 |
Lixte Biotechnology Holdings
LIXT
|
-62.9 | - | - | $ 63.4 M | USA |
 |
Magenta Therapeutics
MGTA
|
-32.9 | - | -7.74 % | $ 41.6 M | USA |
 |
NovaBay Pharmaceuticals
NBY
|
99.84 | - | - | $ 11.3 M | USA |
 |
NeuroBo Pharmaceuticals
NRBO
|
-243.26 | - | 0.43 % | $ 12 M | USA |
 |
OncoCyte Corporation
OCX
|
0.16 | - | 17.22 % | $ 355 K | USA |
 |
Onconova Therapeutics
ONTX
|
-1457.87 | - | -0.47 % | $ 21 M | USA |
 |
Opthea Limited
OPT
|
80.96 | - | - | $ 1.2 B |  Australia |